Profound Medical (PROF) Reports Q3 Loss, Tops Revenue Estimates

Core Insights - Profound Medical reported a quarterly loss of $0.26 per share, better than the Zacks Consensus Estimate of a loss of $0.38, marking an earnings surprise of +31.58% [1] - The company generated revenues of $5.29 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 0.74% and showing a significant increase from $2.83 million a year ago [2] - Profound Medical shares have declined approximately 13.9% year-to-date, contrasting with the S&P 500's gain of 16.5% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.34 on revenues of $8 million, while for the current fiscal year, it is -$1.58 on revenues of $15.6 million [7] - The estimate revisions trend for Profound Medical was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Medical - Drugs industry, to which Profound Medical belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]